{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:22:40Z","timestamp":1791246160391,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1136\/ard.2011.150326","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T20:20:49Z","timestamp":1311970849000},"page":"2029-2036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":382,"title":["Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway"],"prefix":"10.1016","volume":"70","author":[{"given":"Brandon W","family":"Higgs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy I","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Morehouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Brohawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Kiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahija","family":"Jallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1136\/ard.2011.150326_bib1","first-page":"S16","article-title":"Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment \u2013 data from randomized clinical trials.","volume":"65","author":"Kavanaugh","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1136\/ard.2011.150326_bib2","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/ard.2011.150326_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nbt0909-779","article-title":"Human Genome Sciences trial data wow lupus community.","volume":"27","author":"Ratner","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1136\/ard.2011.150326_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity.","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard.2011.150326_bib5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1191\/096120300674499064","article-title":"Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies.","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"key":"10.1136\/ard.2011.150326_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease.","volume":"301","author":"Hooks","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2011.150326_bib7","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/art.11226","article-title":"Interferon-alpha: a new target for therapy in systemic lupus erythematosus?","volume":"48","author":"Crow","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib8","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-alpha\/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib9","first-page":"S526","article-title":"MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus.","volume":"56","author":"Wallace","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib10","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis.","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1136\/ard.2011.150326_bib12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/ard.2006.063412","article-title":"Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.","volume":"66","author":"van der Pouw Kraan","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2011.150326_bib13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sj\u00f6gren's syndrome: a possible etiopathogenic mechanism.","volume":"52","author":"B\u00e5ve","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","article-title":"Systemic sclerosis and lupus: points in an interferon-mediated continuum.","volume":"62","author":"Assassi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib15","first-page":"pii","article-title":"Development of potential pharmacodynamic and diagnostic markers for anti-IFN-a monoclonal antibody trials in systemic lupus erythematosus.","volume":"2009","author":"Yao","year":"2009","journal-title":"Hum Genomics Proteomics"},{"key":"10.1136\/ard.2011.150326_bib16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus.","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib17","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib19","doi-asserted-by":"crossref","first-page":"e2737","DOI":"10.1371\/journal.pone.0002737","article-title":"Type I interferon: potential therapeutic target for psoriasis?","volume":"3","author":"Yao","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1136\/ard.2011.150326_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/art.27226","article-title":"Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta\/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.","volume":"62","author":"Mavragani","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib21","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/art.23619","article-title":"Age- and sex-related patterns of serum interferon-alpha activity in lupus families.","volume":"58","author":"Niewold","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib22","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.106.613638","article-title":"Rank score tests.","volume":"114","author":"LaVange","year":"2006","journal-title":"Circulation"},{"key":"10.1136\/ard.2011.150326_bib23","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","article-title":"Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.","volume":"95","author":"Der","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2011.150326_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2011.150326_bib25","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2011.150326_bib26","doi-asserted-by":"crossref","first-page":"F59","DOI":"10.1084\/jem.194.12.f59","article-title":"A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus.","volume":"194","author":"R\u00f6nnblom","year":"2001","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2011.150326_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rdc.2009.12.008","article-title":"Interferon-alpha: a therapeutic target in systemic lupus erythematosus.","volume":"36","author":"Crow","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2011.150326_bib28","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","article-title":"Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis.","volume":"168","author":"Tezak","year":"2002","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"10.1136\/ard.2011.150326_bib29","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar2885","article-title":"Type 1 interferons and myositis.","volume":"12","author":"Greenberg","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2011.150326_bib30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archderm.144.10.1379","article-title":"Type I interferon in the induction or exacerbation of dermatomyositis: what this observation tells us about the naturally occurring disease.","volume":"144","author":"Fiorentino","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1136\/ard.2011.150326_bib31","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren's syndrome.","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2011.150326_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/gene.2009.20","article-title":"Peripheral blood gene expression profiling in Sj\u00f6gren's syndrome.","volume":"10","author":"Emamian","year":"2009","journal-title":"Genes Immun"},{"key":"10.1136\/ard.2011.150326_bib33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/08916930903510914","article-title":"The type I IFN system in rheumatoid arthritis.","volume":"43","author":"Conigliaro","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1136\/ard.2011.150326_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.gene.6364438","article-title":"Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients.","volume":"9","author":"van der Pouw Kraan","year":"2008","journal-title":"Genes Immun"},{"key":"10.1136\/ard.2011.150326_bib35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/art.27294","article-title":"Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis.","volume":"62","author":"van Baarsen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib36","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.23486","article-title":"Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.","volume":"58","author":"Kim","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.imlet.2008.03.016","article-title":"Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma?","volume":"118","author":"Coelho","year":"2008","journal-title":"Immunol Lett"},{"key":"10.1136\/ard.2011.150326_bib38","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2011.150326_bib39","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis.","volume":"69","author":"Eloranta","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2011.150326_bib40","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/ken083","article-title":"Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.","volume":"47","author":"Sekiguchi","year":"2008","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724190978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724190978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2011.150326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:31:31Z","timestamp":1737333091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724190978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0003496724190978"],"URL":"https:\/\/doi.org\/10.1136\/ard.2011.150326","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2011.150326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}